Introducing Rosetta Commons Foundation and Levitate Bio

Dear members of the Rosetta Community,

The Rosetta Commons Board is excited to announce a significant milestone in the evolution of our community and a step on our path toward the Future of Rosetta. We have created a non-profit organization, the Rosetta Commons Foundation, which has established a wholly-owned subsidiary company called Levitate Bio. Levitate Bio provides cloud-based automated protein modeling and design protocols using AI & Rosetta, available through annual subscriptions.


With a mission similar to the Rosetta Commons, the Rosetta Commons Foundation aims to foster a collaborative community that contributes to knowledge and tools for computational modeling and design of biological macromolecules. Appointed by the Rosetta Commons Board, the Foundation’s initial Board currently consists of Jeff Gray, Julia Koehler Leman, and David Nannemann. We expect this leadership structure to evolve soon, with a more permanent Board structure announced in due course.


What is unique about the Rosetta Commons Foundation? It is a nonprofit organization that serves as the sole equity owner of Levitate Bio, a setup that would allow profits from Levitate Bio to flow back to the parent organization. Rosetta Commons community activities, such as education, conferences, and scientific research, may be supported with these funds. Moving forward, we welcome input from the Rosetta Commons community about these new entities.


Levitate Bio is a spin-out of Cyrus Biotechnology. It will advance software tools built on the Rosetta software suite and state-of-the-art AI technologies. Bringing the power of biomolecular structure prediction and design to a wider audience continues the acceleration of scientific discovery and development. Levitate Bio is led by Sam DeLuca as CEO and Karen Khar as VP of Sales and Business Development. Both have deep roots in our community, honing their expertise over many years.


This is an exciting time for the Rosetta Commons. The formation of the Rosetta Commons Foundation and its relationship to Levitate Bio represents a commitment to growth, sustainability, and broad impact. Thank you for your continued commitment and trust in our community. 


If you have any questions or would like to know more about what this means for our community, you can submit your questions HERE or reach out to me (jgray at jhu dot edu) and Rosetta Commons Industry Chair David Nannemann (david at rosettadesigngroup dot com). As always, we appreciate all input and welcome partnership in these milestones.


On behalf of the Rosetta Commons Board,

Jeff


The Rosetta Commons Board

Jeff Gray - Director

Steffen Lindert - Treasurer

Camille Matthis - Secretary

Rocco Moretti - Documentation Chair

Colin Smith - Membership Chair

Ora Schueler-Furman - Awards Chair

Firas Khatib - Diversity Chair

Dominik Gront - Safety Officer

Ashley Vater - Workforce Development Chair

Julia Koehler Leman - Conference Executive Chair

David Nannemann - Industry Chair

Alena Khmelinskaia - Early Career Faculty Chair

Brian Weitzner - At-large Member

Comments

Post a Comment

Popular posts from this blog

Announcing the winners of the Winter Protein Design Games 2024: Unleashing Innovation in Enzyme Engineering

Image
The Winter RosettaCon organizers want to thank Liberum Bio for sponsoring the experimental validation of the designs that they carried out in 8 days starting from digital sequences! Liberum Bio produces proteins at high yields in cell-free systems at a fraction of the usual cost and time via highly engineered strains and state-of-the art reaction mixtures. At Winter RosettaCon 2024 in Boston, the Rosetta Commons in partnership with Liberum Biotech hosted the inaugural Winter Protein Design Games , focusing on the design of Tobacco Etch Virus (TEV) protease variants. TEV protease is commonly used as a tool for sequence-specific protein cleavage, facilitating the purification of proteins without affinity tags. The competition challenged cross-institutional participating teams to engineer TEV proteases that exhibited enhanced substrate cleavage efficiency over the wild-type enzyme.  The competition was straightforward: design TEV protease variants that outperform the wild type in cl...
Read more

Announcing Rosetta's Transition to a Public Repository (including Licensing Changes)

Dear Rosetta Community and users of Rosetta, We're excited to announce that we have moved the Rosetta code repository to a public repository! We have made this move to honor our longstanding philosophy of sharing our work publicly and making it broadly accessible to scientists. This change marks a new chapter for Rosetta, where future developments will be more collaborative and accessible.  This move required crucial changes to our workflow and licensing terms that are designed to streamline contributions to our platform. The new repository is accessible at https://github.com/RosettaCommons/rosetta . Licensing adjustments: The repository's public status means that non-commercial users no longer need to explicitly sign up for a license to access Rosetta. However, despite being publicly accessible, Rosetta is not open source; redistribution restrictions and other licensing restrictions remain in place for all users. For our commercial users, the existing license will continue as...
Read more